Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1β release

Miltefosine is an FDA approved oral drug for treating cutaneous and visceral leishmaniasis. Leishmania is a flagellated protozoa, which infects and differentiates in macrophages. Here, we studied the effects of Miltefosine on macrophage’s lipid homeostasis, autophagy, and NLRP3 inflammasome assembly...

Descripción completa

Detalles Bibliográficos
Autores principales: Iacano, Amanda J., Lewis, Harvey, Hazen, Jennie E., Andro, Heather, Smith, Jonathan D., Gulshan, Kailash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668382/
https://www.ncbi.nlm.nih.gov/pubmed/31366948
http://dx.doi.org/10.1038/s41598-019-47610-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668382/
https://www.ncbi.nlm.nih.gov/pubmed/31366948
http://dx.doi.org/10.1038/s41598-019-47610-w

Ejemplares similares